EurekaMag
+ Most Popular
Cunninghamia lanceolata plantations in China
Mammalian lairs in paleo ecological studies and palynology
Studies on technological possibilities in utilization of anhydrous milk fat for production of recombined butter-like products
Should right-sided fibroelastomas be operated upon?
Large esophageal lipoma
Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions
Poissons characoides nouveaux ou non signales de l'Ilha do Bananal, Bresil
Desensitizing efficacy of Colgate Sensitive Maximum Strength and Fresh Mint Sensodyne dentifrices
Administration of fluid by subcutaneous infusion: revival of a forgotten method
Tundra mosquito control - an impossible dream?
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
Geochemical pattern analysis; method of describing the Southeastern limestone regional aquifer system
Incidence of low birth weights in a hospital of Mexico City
Tabanidae
Graded management intensity of grassland systems for enhancing floristic diversity
Microbiology and biochemistry of cheese and fermented milk
The ember tetra: a new pygmy characid tetra from the Rio das Mortes, Brazil, Hyphessobrycon amandae sp. n. (Pisces, Characoidei)
Risk factors of contrast-induced nephropathy in patients after coronary artery intervention
Renovation of onsite domestic wastewater in a poorly drained soil
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Haematological studies in rats fed with metanil yellow
Studies on pasteurellosis. I. A new species of Pasteurella encountered in chronic fowl cholera
Dormancy breaking and germination of Acacia salicina Lindl. seeds
therapy of lupus nephritis. a two-year prospective study

A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia


A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia



Journal of the American Medical Association 260(3): 359-366



ISSN/ISBN: 0002-9955

DOI: 10.1001/jama.1988.03410030075032

This study compares lovastatin and cholestyramine resin therapy in patients with severe primary hypercholesterolemia. Two hundred sixty-four patients on lipid-lowering diets were randomized equally to receive 12 g of cholestyramine resin, 20mg of lovastatin, or 40 mg of lovastatin, each twice a day. The mean reductions among the three groups after 12 weeks' treatment in levels of total plasma cholesterol (-17%, -27%, and -34%, respectively) and low-density lipoprotein cholesterol (-23%, -32%, and -42%, respectively) and the median reductions in apolipoprotein B levels (-21%, -28%, and -33%, respectively) were all significantly different between groups. Similar mean increases in high-density lipoprotein cholesterol levels (8%, 9%, and 8%, respectively) and median increases in apolipoprotein A-I levels (7%, 6%, and 11%, respectively) were observed in all treatment groups. Cholestyramine resin treatment had no significant effect on very low-density lipoprotein cholesterol and apolipoprotein A-II levels and produced a median 11% increase in plasma triglyceride concentration; in contrast, administration of either 20 or 40 mg of lovastatin twice a day was associated with median reductions in very low-density lipoprotein cholesterol levels (-34% and -31%, respectively) and plasma triglyceride levels (-21% and -27%, respectively) and median increases in levels of apolipoprotein A-II (8% and 13%, respectively). Adverse events in all treatment groups were preponderantly in the gastrointestinal tract; gastrointestinal tract symptoms that could be attributed to therapy with a specific drug occurred in 58% of the cholestryamine resin group, 13% of the 20-mg lovastatin group, and 14% of the 40-mg lovastatin group. The only drug-attributable serious adverse event was a reversible myopathy in a patient taking 40 mg of lovastatin twice a day. We conclude that lovastatin is both more effective and better tolerated than cholestyramine resin in the treatment of primary hypercholesterolemia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 004590402

Download citation: RISBibTeXText

Related references

A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III. JAMA 260(3): 359-366, 1988

Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia. Medicina Clinica 106(20): 776-779, 1996

A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. American Journal of Cardiology 66(8): 22B-30B, 1990

Lovastatin vs cholestyramine therapy for primary hypercholesterolemia. JAMA 260(24): 3590-3591, 1988

Comparison of lovastatin and cholestyramine for the treatment of primary hypercholesterolemia. Arteriosclerosis 7(5): 517A, 1987

Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia. Journal of Cardiovascular Pharmacology 22(3): 396-400, 1993

Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment of hypercholesterolemia. Journal of Cardiovascular Pharmacology 18(4): 496-503, 1991

Comparison between lovastatin and cholestyramine in the treatment of moderate to severe primary hypercholesterolaemia. Annals of Medicine 24(2): 121-127, 1992

Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. American Journal of Cardiology 62(15): 35J-43J, 1988

Efficacy of combination cholestyramine and lovastatin therapy for the treatment of hypercholesterolemia. Journal of the American College of Cardiology 17(2 Suppl A): 188A, 1991

Homozygous familial hypercholesterolemia. Response to combined cholestyramine and lovastatin therapy. Anales Espanoles de Pediatria 33(1): 58-60, 1990

Comparison of atorvastatin alone versus simvastatin cholestyramine in the management of severe primary hypercholesterolemia (The Six Cities Study). Internal Medicine Journal 28(3): 327-333, 1998

A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism, Clinical and Experimental 41(5): 498-503, 1992

Lovastatin in primary hypercholesterolemia. A Norwegian multicenter study. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 112(29): 3665-3669, 1992

Evaluation of the hypolipidemic effects of lovastatin in primary hypercholesterolemia: Multicenter study. Kardiologiya 33(11): 5-6, 48-54, 1993